Aclaris Therapeutics, Inc. Form SC 13G/A February 14, 2018

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

#### **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 1)\*

**Aclaris Therapeutics, Inc.** 

(Name of Issuer)

Common Stock, \$0.00001 par value

(Title of Class of Securities)

00461U 10 5

(CUSIP Number)

**December 31, 2017** 

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

# Edgar Filing: Aclaris Therapeutics, Inc. - Form SC 13G/A

Rule 13d-1(c)

Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

| 1                                      | NAME           | NAMES OF REPORTING PERSONS  |  |  |  |
|--|----------------|---|--|--|--|
|  | I.R.S. II      | DENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)                                   |  |  |  |
| 2                                      | _              | ve Advisors LLC<br>THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (b) |  |  |  |
| 3                                      | SEC US         | SEC USE ONLY  |  |  |  |
| 4 CITIZENSHIP OR PLACE OF ORGANIZATION |                |   |  |  |  |
|  | Delawa         | re<br>5 SOLE VOTING POWER   |  |  |  |
| N                                      | UMBER OF       |   |  |  |  |
|  | SHARES         | 0<br>6 SHARED VOTING POWER  |  |  |  |
| BE                                     | NEFICIALLY     |   |  |  |  |
| O                                      | OWNED BY  EACH | 0<br>7 SOLE DISPOSITIVE POWER   |  |  |  |
| R                                      | EPORTING       |   |  |  |  |
|  | PERSON         | 0<br>8 SHARED DISPOSITIVE POWER   |  |  |  |
|  | WITH:          |   |  |  |  |
| 9                                      | AGGRI          | 0<br>EGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                         |  |  |  |
| 10                                     |                | BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE<br>JCTIONS)       |  |  |  |

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 0%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA

| 1    | AMES OF REPORTING PERSONS   |  |  |  |
|------|---|--|--|--|
|      | I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)                                     |  |  |  |
| 2    | Joseph Edelman CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) (b)     |  |  |  |
| 3    | SEC USE ONLY  |  |  |  |
| 4    | CITIZENSHIP OR PLACE OF ORGANIZATION  |  |  |  |
|      | United States of America 5 SOLE VOTING POWER  |  |  |  |
| NUN  | MBER OF   |  |  |  |
|      | HARES 0 6 SHARED VOTING POWER   |  |  |  |
| BENE | EFICIALLY   |  |  |  |
|      | NED BY  0  FACH  7 SOLE DISPOSITIVE POWER   |  |  |  |
| REP  | PORTING   |  |  |  |
|      | ERSON 0 8 SHARED DISPOSITIVE POWER WITH:  |  |  |  |
| 9    | 0<br>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                               |  |  |  |
| 10   | 0<br>CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE<br>INSTRUCTIONS) |  |  |  |

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 0%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

| 1                                      | NAME             | NAMES OF REPORTING PERSONS |   |  |  |  |
|--|------------------|----------------------------|---|--|--|--|
|  | I.R.S. I         | DE)                        | NTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   |  |  |  |
| 2                                      |                  | K T                        | Life Sciences Master Fund, Ltd. HE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) b) |  |  |  |
| 3                                      | SEC U            | SEC USE ONLY               |   |  |  |  |
| 4 CITIZENSHIP OR PLACE OF ORGANIZATION |                  |                            |   |  |  |  |
|  | Cayma            |                            | lands<br>SOLE VOTING POWER  |  |  |  |
| N                                      | UMBER OF         |                            |   |  |  |  |
|  | SHARES           | 6                          | 0<br>SHARED VOTING POWER  |  |  |  |
| BE                                     | NEFICIALLY       | •                          |   |  |  |  |
| C                                      | OWNED BY<br>EACH | 7                          | 0<br>SOLE DISPOSITIVE POWER   |  |  |  |
| R                                      | REPORTING        |                            |   |  |  |  |
|  | PERSON WITH:     | 8                          | 0<br>SHARED DISPOSITIVE POWER   |  |  |  |
| 9                                      | AGGR             | EG                         | 0<br>ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON                                     |  |  |  |
| 10                                     |                  |                            | OX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE<br>ΓΙΟΝS)                    |  |  |  |

- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
  - 0%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

## Item 1(a). Name of Issuer:

Aclaris Therapeutics, Inc. (the Issuer )

### Item 1(b). Address of Issuer s Principal Executive Offices:

101 Lindenwood Drive, Suite 400, Malvern, PA 19355

# Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the Reporting Persons ) are:

Perceptive Advisors LLC ( Perceptive Advisors )

Joseph Edelman (Mr. Edelman)

Perceptive Life Sciences Master Fund, Ltd. (the Master Fund )

# Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor

New York, NY 10003

#### Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

# Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.00001 par value ( Common Stock )

### Item 2(e). CUSIP Number:

00461U 10 5

#### Item 3.

# Edgar Filing: Aclaris Therapeutics, Inc. - Form SC 13G/A

# If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

# Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.

### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

# Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

# Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.</u>

Not applicable.

# Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

### Item 9. <u>Notice of Dissolution of Group.</u>

Not applicable.

#### Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

## **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2018

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member